Literature DB >> 30221156

Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection?

Stefan Heinrich1.   

Abstract

Entities:  

Year:  2018        PMID： 30221156      PMCID： PMC6131267          DOI： 10.21037/hbsn.2018.03.11

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  10 in total

Review 1.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Authors:  Mustafa Suker; Berend R Beumer; Eran Sadot; Lysiane Marthey; Jason E Faris; Eric A Mellon; Bassel F El-Rayes; Andrea Wang-Gillam; Jill Lacy; Peter J Hosein; Sing Yu Moorcraft; Thierry Conroy; Florian Hohla; Peter Allen; Julien Taieb; Theodore S Hong; Ravi Shridhar; Ian Chau; Casper H van Eijck; Bas Groot Koerkamp
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316

2.  Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies.

Authors:  Hiroshi Haeno; Mithat Gonen; Meghan B Davis; Joseph M Herman; Christine A Iacobuzio-Donahue; Franziska Michor
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

Review 3.  The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.

Authors:  Stephan Schorn; Ihsan Ekin Demir; Carmen Mota Reyes; Cemil Saricaoglu; Nicole Samm; Rebekka Schirren; Elke Tieftrunk; Daniel Hartmann; Helmut Friess; Güralp Onur Ceyhan
Journal:  Cancer Treat Rev       Date:  2017-03-14       Impact factor: 12.111

4.  Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival.

Authors:  Fengchun Lu; Kevin C Soares; Jin He; Ammar A Javed; John L Cameron; Neda Rezaee; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss
Journal:  Hepatobiliary Surg Nutr       Date:  2017-06       Impact factor: 7.293

5.  Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma.

Authors:  Saburo Fukuda; Elie Oussoultzoglou; Philippe Bachellier; Edoardo Rosso; Hiroshi Nakano; Maxime Audet; Daniel Jaeck
Journal:  Arch Surg       Date:  2007-02

6.  Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome.

Authors:  T A Sohn; K D Lillemoe; J L Cameron; H A Pitt; J J Huang; R H Hruban; C J Yeo
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

7.  Pancreatic Cancer Surgery: The New R-status Counts.

Authors:  Oliver Strobel; Thomas Hank; Ulf Hinz; Frank Bergmann; Lutz Schneider; Christoph Springfeld; Dirk Jäger; Peter Schirmacher; Thilo Hackert; Markus W Büchler
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

8.  Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.

Authors:  Ali A Mokdad; Rebecca M Minter; Hong Zhu; Mathew M Augustine; Matthew R Porembka; Sam C Wang; Adam C Yopp; John C Mansour; Michael A Choti; Patricio M Polanco
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

9.  Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?

Authors:  S Crippa; A Bittoni; E Sebastiani; S Partelli; S Zanon; A Lanese; K Andrikou; F Muffatti; G Balzano; M Reni; S Cascinu; M Falconi
Journal:  Eur J Surg Oncol       Date:  2016-06-29       Impact factor: 4.424

Review 10.  Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.

Authors:  Stefan Heinrich; Hauke Lang
Journal:  Int J Mol Sci       Date:  2017-07-26       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.